FIGURE 3.

Ciglitazone significantly reduces bacterial burdens during brain abscess development. Mice (n = 4–6 per group) received i.p. injections of PBS or ciglitazone (10 or 50 mg/kg/day) beginning at 3 days following an intracerebral infection with S. aureus, with treatment continuing daily until termination of the experiment. Animals were sacrificed at either 1 or 3 days after ciglitazone treatment (corresponding to days 4 and 6 post-infection) for quantitation of viable bacteria within abscesses.*, p < 0.05 reflects significant differences between infected PBS- and ciglitazone-treated animals. Results are representative of two independent experiments.